ArticleThe journal of allergy and clinical immunology. Global2022
Age and respiratory syncytial virus etiology in bronchiolitis clinical outcomes.
Article in The journal of allergy and clinical immunology. Global, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention.JAMA network open · 2026Article
- Optimizing pediatric bronchiolitis management through an integrated hub-and-spoke network: evidence from a regional Italian experience.European journal of pediatrics · 2026Observational
- Clinically significant bradycardia in children with respiratory syncytial virus bronchiolitis receiving dexmedetomidine: effect modification by mechanical ventilation.BMJ paediatrics open · 2025Article
- [Validity of case definitions for Severe Acute Respiratory Infection based on ICD-10 codes in four autonomous communities (Spain, 2021-2023)].Revista espanola de salud publica · 2025Article
- Article
- Hospitalizations for bronchiolitis among infants before and after the SARS-CoV-2 pandemic: an area-based study of the Emilia-Romagna Region, Italy.Italian journal of pediatrics · 2025Article
- Bronchiolitis Severity Affects Blood Count and Inflammatory Marker Levels: A Real-Life Experience.Viruses · 2025Article
- Clinical outcomes and severity of laboratory-confirmed RSV compared with influenza, parainfluenza and human metapneumovirus in Australian children attending secondary care.BMJ open respiratory research · 2024Article
- [Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Observational
- Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.Infectious diseases and therapy · 2024Article
- Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.Infectious diseases and therapy · 2024Article
- The risk of hospitalisation from RSV is not increased by co-infection in children under 24-months-of-age.European journal of pediatrics · 2024Article
- Management of Acute Bronchiolitis in Spoke Hospitals in Northern Italy: Analysis and Outcome.Diseases (Basel, Switzerland) · 2024Article
- Clinical Differences between SARS-CoV-2 and RSV Infections in Infants: Findings from a Case-Control Study.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis. Precise and updated information about demographic characteristics, clinical manifestations, and risk factors for severe disease are needed for optimal implementation of upcoming new therapeutic and preventive interventions. Objectives: The main goals of this study were to define the epidemiology of acute bronchiolitis in hospitalized young children during 5 calendar years in Spain; evaluate the differences in clinical manifestations between children hospitalized with RSV infection and those hospitalized with non-RSV infection; and identify demographic characteristics, clinical parameters, and risk factors associated with disease severity. Methods: We performed a retrospective review of the medical records of children younger than 2 years who were hospitalized with bronchiolitis between January 2015 and December 2019. We constructed multivariable models to identify independent predictors of disease severity defined as length of hospital stay (LOS), pediatric intensive care unit (PICU) admission, and need for a high-flow-nasal canula (HFNC). Results: From January 2015 to December 2019, 1437 children were hospitalized with bronchiolitis and met the inclusion criteria. The proportion of children hospitalized with bronchiolitis caused by RSV increased significantly during the study period, from 60% to 65% ( Conclusion: This study identified differences in disease severity between young children with RSV bronchiolitis and those with non-RSV bronchiolitis. These differences are particularly significant in children younger than 6 months, who comprise a group of infants with suboptimal innate immunity to RSV and may benefit from new preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.